BioReference broadens CV test access:
This article was originally published in Clinica
Executive Summary
LipoScience has provided BioReference Laboratories with access to its NMR LipoProfile test, so that the latter can use the technology in its new Advanced Cardiovascular Testing (ACT) programme. ACT is aimed at providing comprehensive cardiovascular reports, and will utilise the LipoProfile, which uses NMR spectroscopy to analyse blood plasma samples and inform doctors on the amount of low-density lipoprotein (LDL) particles present. LDL particles transport cholesterol from the liver, and are an indicator of potential heart disease and atherosclerosis levels. This collaboration is in line with LipoScience's goal of broadening the access of the LipoProfile test.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.